Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
Lonza announced on October 29, 2026, a further expansion of its
"As more ADCs and other bioconjugates advance towards commercialization, customers need confidence that manufacturing capacity can grow with their programs," said
The investments fall into 2 complementary parts. First, Lonza is converting existing mid-scale bioconjugation suites into a standardized
Second, the new large-scale bioconjugation facility under construction at the Visp complex will include 3 multiproduct suites for cytotoxic and noncytotoxic products.¹ The suites will offer stainless-steel and single-use manufacturing at scales of up to 1200 L, with capacity expected to be operational from 2028 to support high-throughput commercial supply.¹
The
Lonza attributed the expansion to the growing number of ADCs and other bioconjugates progressing through clinical development toward commercialization.¹ That pipeline has been visible in recent late-stage data, including programs built on newer formats such as
At the European Society for Medical Oncology (ESMO) 2026 Congress, SystImmune and Bristol Myers Squibb reported phase 3 PANKU-Lung01 results for
In addition, GSK licensor Hansoh Pharmaceutical reported that the B7-H3-targeted ADC
As candidates like these move toward potential approval, their sponsors will need commercial-scale conjugation capacity, the type of capacity Lonza's Visp expansion is designed to provide.
The new large-scale capacity is not expected to be operational until 2028, and construction and qualification timelines can shift. Lonza did not disclose the investment amount, customer commitments, or projected output. Demand for ADC capacity depends on clinical and regulatory outcomes for individual programs, which remain uncertain.
